The US Food and Drug Administration (FDA) has approved the investigational new drug (IND) application for Shanghai Junshi Biosciences’ anti-CD112R monoclonal antibody (TAB009/JS009) to treat advanced solid tumours.
Women’s healthcare firm Organon has signed an agreement with Daré Bioscience for latter's Xaciato (clindamycin phosphate vaginal gel, 2%).
LifeMine Therapeutics has raised $175m in a Series C financing to advance Avatar-Rx, its evolutionarily derived genomic drug discovery platform.
Biotechnology firm Affini-T Therapeutics has raised $175m in an oversubscribed financing round for advancing T cell therapies for solid tumour patients with oncogenic driver mutations.
Triumvira Immunologics has completed an extension of Series A financing, which brings the total round to nearly $100m, for supporting the continued preclinical and clinical development of its T cell Antigen Coupler (TAC)-T cell therapy programmes.
Sanofi has announced a collaboration with investment management firm Blackstone to advance an innovative treatment for multiple myeloma.
Erasca and Eli Lilly and Company have signed a clinical trial partnership and supply agreement to evaluate ERAS-007, an oral ERK1/2 inhibitor, in combination with Eli Lilly's anti-EGFR antibody cetuximab (ERBITUX).
Salubris Biotherapeutics has secured $32m in financing from Shenzhen Salubris Pharmaceuticals to advance its new complex biologics for oncology, cardiovascular and neurodegenerative diseases.
Helsinn Group has announced an update to its existing collaboration with BridgeBio Pharma to develop, produce and commercialise infigratinib for oncology indications in the US.
Epsilogen has raised $41.011m (£30.75m) in a Series B funding round led by new investor Novartis Venture Fund to further develop IgE-based antibody candidates for cancer treatment.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.